Acute-On-Chronic Liver Failure

Gastroenterology
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Grifols
GrifolsNEW YORK, NY
1 program
1
SMT + PE-A 5%Phase 31 trial
Active Trials
NCT03702920TerminatedEst. Apr 2025
CytoSorbents
CytoSorbentsPRINCETON, NJ
1 program
CytoSorbN/A1 trial
Active Trials
NCT06079021Recruiting20Est. Sep 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
GrifolsSMT + PE-A 5%
CytoSorbentsCytoSorb

Clinical Trials (2)

Total enrollment: 20 patients across 2 trials

NCT03702920GrifolsSMT + PE-A 5%

Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%

Start: Feb 2019Est. completion: Apr 2025
Phase 3Terminated

COOLEY- Study: ACute on ChrOnic Liver FailurE Using the CYtosorb Device

Start: Jun 2024Est. completion: Sep 202720 patients
N/ARecruiting

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 20 patients
2 companies competing in this space